VGXI, a plasmid DNA contract manufacturing organization, unveiled the grand opening of a facility expansion which includes flexible scale plasmid DNA manufacturing space as well as purpose-built GMP production areas for RNA synthesis.
 
Increasing the company’s footprint by 17% and cGMP manufacturing space by over 70%, this expansion was initiated in anticipation of the recently finalized license and partnership with Houston Methodist Research Institute (HMRI). Under the partnership, technology transfer for clinical grade RNA manufacturing capabilities is already underway from HMRI, providing an ideal complement to VGXI’s existing DNA production services.
 
The ribbon cutting ceremony was attended by U.S. Congressman Kevin Brady as well representatives of the Texas biotechnology community, including BioHouston chief executive officer, Ann Tanabe. During the ceremony Congressman Brady presented VGXI’s president and chief executive officer, Young Park with a commendation on behalf of the U.S. House of Representatives for the company’s continued contributions to the biotechnology industry and local community.
 
In response to the growing success and worldwide demand for gene-based medicines, VGXI has continued to improve and broaden their services with three facility expansions in just the past 4 years. According to Mr. Park, “The current expansion is just one part of the company’s overall plan to keep pace with industry. We are already evaluating locations for VGXI’s next phase facility for commercial DNA and RNA production.”